Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to…
HERE'S WHAT THE ?? STOCK MARKET LOOKED LIKE TODAY Up: Meta $META +3.4% Accenture $ACN +2.8% Verizon $VZ +2.7% Boston Scientific $BSX +2.7% ConocoPhillips $COP +2.6% Prologis $PLD +2.3% Elevance Health $ELV +2.3% TJX $TJX +2.3% Down: Ciena $CIEN -10.0% Lumentum $LITE -9.8% Bloom…
Fair Issac $FICO is currently the worst performing stock in the S&P 500 so far in 2026 Here are the top 10 worst performing stocks in the S&P 500 so far in 2026 Fair Issac $FICO - 61%? AppLovin $APP -59%? Costar $CSGP -56% ? Boston Scientific $BSX -55%? Lululemon $LULU…
CITI ADDS FOUR STOCKS TO 90-DAY UPSIDE CATALYST WATCH Citi has added four healthcare stocks to its 90-Day Upside Catalyst Watch List: • Sight Sciences ( $SGHT) • Zimmer Biomet ( $ZBH) • Edwards Lifesciences ( $EW) • Boston Scientific ( $BSX) The additions signal Citi sees
31 analysts rate BSX Buy on consensus.
Consensus price target: $58.00 (+26.94% upside from $45.69)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Morano Susan E director | Aug 25, 2026 | Purchase | 2,040 | $100.41K |
| Habiger David C director | Aug 5, 2026 | Purchase | 2,100 | $99.94K |
| Habiger David C director | Aug 4, 2026 | Purchase | 140 | $6.8K |
| Mahoney Michael F director, Chairman, President & CEO | Aug 3, 2026 | Purchase | 186,240 | $9M |
| Habiger David C director | Aug 3, 2026 | Purchase | 1,042 | $50.08K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $20.07B | +19.87% | $2.89B |
| 2024 | $16.75B | +17.61% | $1.85B |
| 2023 | $14.24B | +12.29% | $1.59B |
Stock data for BSX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics